• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Oruka Therapeutics, Inc. - Common Stock (NQ:ORKA)

    66.46 +3.88 (+6.20%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,218,234
    Open 61.40
    Bid (Size) 65.00 (300)
    Ask (Size) 67.50 (300)
    Prev. Close 62.58
    Today's Range 60.98 - 66.63
    52wk Range 8.910 - 91.00
    Shares Outstanding 14,410,143
    Dividend Yield 29.12%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering
    From Oruka Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
    From Oruka Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +135.1%
    +135.1%
    1 Month
    +24.7%
    +24.7%
    3 Month
    +93.8%
    +93.8%
    6 Month
    +153.8%
    +153.8%
    1 Year
    +520.5%
    +520.5%

    More News

    Read More
    These stocks are gapping in today's session ↗
    Via Chartmill
    MoonLake Stock Climbs After-Hours: Retail Traders Shrug Off Record Plunge, More Wall Street Downgrades ↗
    Via Stocktwits
    Top movers in Monday's pre-market session ↗
    Via Chartmill
    News headline image
    Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
    From Oruka Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
    From Oruka Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Oruka Insider Sells $463K in Stock as Shares Skyrocket 650%, but Here's What Matters for Investors ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
    Via The Motley Fool
    News headline image
    What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    VR Adviser Adds Over 1 Million Savara Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    Let's take a look at the stocks that are in motion in today's session. ↗
    Via Chartmill
    News headline image
    Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
    From Oruka Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Oruka Therapeutics to Participate in Multiple Upcoming Conferences
    From Oruka Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001
    From Oruka Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Oruka Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Oruka Therapeutics Announces New Board Member and Board Transition
    From Oruka Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
    Via Benzinga
    News headline image
    AutoZone To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Thursday ↗
    Via Benzinga
    News headline image
    Oruka Therapeutics Inc (NASDAQ:ORKA) Reports Q3 2025 Results, Beats EPS Estimates and Provides Clinical Pipeline Updates ↗
    Via Chartmill
    News headline image
    Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    From Oruka Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    The Insider Report: The Bulls Can Thank Tech ↗
    Via Benzinga
    News headline image
    Oruka Therapeutics to Present at Multiple November Investor Conferences
    From Oruka Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Stock Market Today: Nasdaq, S&P 500 Futures Rise As Government Enters 2nd Week Of Shutdown—Plug, Lithium Americas, UiPath In Focus ↗
    Via Benzinga
    Topics Stocks
    News headline image
    Constellation Brands, Aehr Test Systems And 3 Stocks To Watch Heading Into Monday ↗
    Via Benzinga

    Frequently Asked Questions

    Is Oruka Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Oruka Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Oruka Therapeutics, Inc. - Common Stock trade on?
    Oruka Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Oruka Therapeutics, Inc. - Common Stock?
    The ticker symbol for Oruka Therapeutics, Inc. - Common Stock is ORKA on the Nasdaq Stock Market
    What is the current price of Oruka Therapeutics, Inc. - Common Stock?
    The current price of Oruka Therapeutics, Inc. - Common Stock is 66.46
    When was Oruka Therapeutics, Inc. - Common Stock last traded?
    The last trade of Oruka Therapeutics, Inc. - Common Stock was at 05/04/26 04:00 PM ET
    What is the market capitalization of Oruka Therapeutics, Inc. - Common Stock?
    The market capitalization of Oruka Therapeutics, Inc. - Common Stock is 957.70M
    How many shares of Oruka Therapeutics, Inc. - Common Stock are outstanding?
    Oruka Therapeutics, Inc. - Common Stock has 958M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.